Statement from FDA on continuing efforts to maintain its strong oversight of generic drugs
date:Feb 25, 2019
product, and other comorbidities, which makes drawing a causal relationship to one particular manufacturer very difficult.

So, how does the FDA identify and track potential safety signals with a specific drug?

When the FDA investigates a possible drug safety concern, a multidisciplinary team reviews the data. Interpreting postmarket safety data is complex. It involves analysis of a wide range of information, including spontaneous reports of adverse drug events, controlled clinical trials and e
18/35 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/20 10:58